Julio Chavez
Overview
Explore the profile of Julio Chavez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoogland A, Li X, Modi K, Welniak T, Rodriguez Y, Irizarry-Arroyo N, et al.
Transplant Cell Ther
. 2024 Dec;
31(3):157.e1-157.e13.
PMID: 39733840
Axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor T-cell therapy, has significantly improved clinical outcomes in adult patients with relapsed/refractory large B-cell lymphoma. However, few studies have examined patient-reported outcomes (PROs)...
2.
Iqbal M, Kumar A, Dreger P, Chavez J, Sauter C, Sureda A, et al.
Transplant Cell Ther
. 2024 Jul;
30(9):832-843.
PMID: 38972511
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL), accounting for nearly one-third of all NHL. The therapeutic landscape for patients with FL has significantly expanded over...
3.
Logothetis C, Horvat N, Kurian T, Bello C, Chavez J, Isenalumhe L, et al.
Oncol Res
. 2024 Jun;
32(6):1031-1036.
PMID: 38827319
Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin's lymphomas. Only one trial...
4.
Zhang Y, Rose A, Khadka S, Cao B, Eatrides J, Saeed H, et al.
Transplant Cell Ther
. 2024 May;
30(9):887.e1-887.e9.
PMID: 38740140
Nodal peripheral T cell lymphomas (PTCLs) are challenging subsets of non-Hodgkin lymphomas characterized by their heterogeneity and aggressive clinical behavior. Given the mixed outcomes reported in previous studies, the efficacy...
5.
Bhansali R, Ellin F, Relander T, Cao M, Li W, Long Q, et al.
Blood Adv
. 2024 May;
8(13):3507-3518.
PMID: 38739715
Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS...
6.
Dong N, Zhang H, Song J, Mammadova J, Shah B, Saeed H, et al.
EJHaem
. 2024 Feb;
5(1):285-289.
PMID: 38406544
No abstract available.
7.
Faramand R, Lee S, Jain M, Cao B, Wang X, Rejeski K, et al.
Blood Cancer Discov
. 2024 Jan;
5(2):106-113.
PMID: 38194367
Significance: CAR T-cell therapy has changed the treatment paradigm for patients with relapsed/refractory hematologic malignancies. Despite encouraging efficacy, a subset of patients have poor clinical outcomes. We show that a...
8.
El Warrak S, Kharfan-Dabaja M, Iqbal M, Hamadani M, Chavez J, Mohty R
Bone Marrow Transplant
. 2023 Dec;
59(2):162-170.
PMID: 38102213
In recent years, chimeric antigen receptor T-cell therapy (CAR T) has revolutionized the treatment landscape for large B cell lymphoma (LBCL), demonstrating remarkable efficacy and ushering a new era of...
9.
Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, et al.
Bone Marrow Transplant
. 2023 Nov;
59(2):211-216.
PMID: 37973893
Outcomes are poor for patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) post chimeric antigen receptor T-cell (CAR-T) therapy. Two CD19-directed therapies, tafasitamab- cxix plus lenalidomide (tafa-len) and...
10.
Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, et al.
Blood Adv
. 2023 Oct;
7(24):7393-7401.
PMID: 37874912
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants...